Amphastar Pharmaceuticals (AMPH) Stock: Buy, Sell, or Hold?
AMPH - Amphastar Pharmaceuticals, Inc.
$23.78
0.24 (1.02%)
▲
5d:
-0.25%
30d:
+19.02%
90d:
+15.83%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When AMPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AMPH shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AMPH shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.83
Based on -3.6% avg growth
INTRINSIC VALUE TODAY
$9.21
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMPH is currently trading at $23.78, which is considered extended relative to its 30-day fair value range of $20.48 to $23.00. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.0) compared to its historical average (6.8). At these levels, the market is pricing in 9.8% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, AMPH is in a uptrend. The price is approaching resistance at $23.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AMPH scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AMPH is in a uptrend. The price is approaching resistance at $23.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AMPH scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$20.48 -
$23.00
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
16.7%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BEARISH: Trading above Wall St target ($22.50)
- BEARISH: Market expects 9.8% growth - appears too optimistic based on history
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$20.48 -
$23.00
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$21.52
Resistance Level
$23.92
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.01
Wall Street Target
$22.50
(-5.4%)
Revenue Growth (YoY)
5.4%
Earnings Growth (YoY)
4.7%
Profit Margin
10.8%
Valuation Premium vs History
+9.8% premium
PE vs Historical
9.0 vs 6.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+9.8%
(market-implied from PE analysis)
1-Year Target
$26.11
(+10%)
2-Year Target
$28.67
(+21%)
3-Year Target
$31.48
(+32%)
3-Yr Target (if PE normalizes)
(PE: 9→7)
PE COMPRESSION
$23.76
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: -11.2%)
$38.82
(+63%)
Base:
(SPY PE: 9.0, Growth: -11.2%)
$17.34
(-27%)
Bear:
(PE: 6.8, Growth: -11.2%)
$13.09
(-45%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 13.93 | Current EPS (TTM): $1.69
Bull Case
$40.45
(+70%)
Analyst growth 56.2%, PE expands to 15.3
Base Case
$36.77
(+55%)
Market implied 56.2%, PE stable at 13.9
Bear Case
$16.01
(-33%)
Severe decline -20.0%, PE contracts to 11.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 10:15 AM ET
Data refreshes hourly during market hours. Next update: 11:14 AM
Data refreshes hourly during market hours. Next update: 11:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
